Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride

Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile o... Biopharmaceuticals, Endocrinology Eli Lilly, Boehringer Ingelheim, Tradjenta, linagliptin, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news